CLIF.F Stock Overview
An investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cordlife Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | S$0.30 |
| 52 Week High | S$0.38 |
| 52 Week Low | S$0.20 |
| Beta | 0.61 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 14.95% |
| 33 Year Change | 10.52% |
| 5 Year Change | 10.52% |
| Change since IPO | -25.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLIF.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.2% |
| 1Y | 15.0% | 2.1% | 31.6% |
Return vs Industry: CLIF.F exceeded the US Healthcare industry which returned 6% over the past year.
Return vs Market: CLIF.F underperformed the US Market which returned 25.1% over the past year.
Price Volatility
| CLIF.F volatility | |
|---|---|
| CLIF.F Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CLIF.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CLIF.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Pang Fai Yiu | www.cordlife.com |
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. The company operates through two segments, Banking and Diagnostics. It offers cord blood, cord lining, and cord tissue banking services, including processing and storage of stem cells; and various diagnostics services, such as newborn genetic screening, pediatric vision and ear screening, pediatric allergen test, genetic talent test, preimplantation genetic screening, endometrial receptivity test, non-invasive prenatal testing, and newborn metabolic screening.
Cordlife Group Limited Fundamentals Summary
| CLIF.F fundamental statistics | |
|---|---|
| Market cap | US$57.25m |
| Earnings (TTM) | US$3.89m |
| Revenue (TTM) | US$42.61m |
14.7x
P/E Ratio1.3x
P/S RatioIs CLIF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLIF.F income statement (TTM) | |
|---|---|
| Revenue | S$57.23m |
| Cost of Revenue | S$18.47m |
| Gross Profit | S$38.76m |
| Other Expenses | S$33.54m |
| Earnings | S$5.22m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.02 |
| Gross Margin | 67.73% |
| Net Profit Margin | 9.12% |
| Debt/Equity Ratio | 0% |
How did CLIF.F perform over the long term?
See historical performance and comparison